Search results for " molecule"

Investigational agents for Crohn's disease.

2010

IMPORTANCE OF THE FIELD: Increased understanding of the biological mechanisms of Crohn's disease has opened the door to a large number of new molecules; some of these are approved for clinical use, while others remain under evaluation. In this review, we examine the clinical efficacy of all the new drugs that have been evaluated in controlled trials in the last 12 years. AREAS COVERED IN THIS REVIEW: Anti-TNF therapy has been reviewed briefly, given the many comprehensive reviews on this topic; attention is focused mainly on the other biological therapies. In assessing the clinical efficacy of these molecules, we consider only the remission rate, as this is considered the most meaningful en…

417 SOLUBLE CELLULAR ADHESION MOLECULES, MYELOPEROXIDASE, AND NEOPTERIN IN METABOLIC SYNDROME PATIENTS WITH STABLE AND UNSTABLE ANGINA PECTORIS

2011

Microalbuminuria and endothelial activation in treated and untreated diabetic and non-diabetic hypertensives

2004

Lovastatin stimulates p75 TNF receptor (TNFR2) expression in primary human endothelial cells

2005

HMG-CoA reductase inhibitors (statins) exert pleiotropic physiological effects. Among others they attenuate cellular responses to genotoxic and inflammatory stress. We investigated the effect of lovastatin on the expression level of TNF receptors (TNFR) in primary human endothelial cells (HUVEC). ELISA, FACS and immunocytochemical analyses show that lovastatin selectively increases the cell surface expression of TNFR2 without affecting the expression level of TNFR1. This effect of lovastatin is independent from inhibition of cell-cycle progression since cells both in G1- and G2-phase showed elevated levels of TNFR2 after lovastatin treatment. To analyze the physiological relevance of lovast…

Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts

1995

OBJECTIVES--To investigate the influence of the Th1 and Th2 lymphokines interleukins (IL)-4 and IL-13, interferon gamma (IFN gamma), and several monokines on the adhesion of mononuclear cells to synovial fibroblasts and intercellular adhesion molecule-1 (ICAM-1) expression and cytokine production of synovial fibroblasts in patients with osteoarthritis. METHODS--Synovial fibroblasts were isolated from patients with osteoarthritis and stimulated with IL-1 beta, IL-4, IL-6, IL-10, IL-12, IL-13, tumour necrosis factor alpha (TNF alpha), and IFN gamma. Subsequently, we determined the production of IL-1 alpha, IL-1 beta, IL-6, IL-10, IL-12, IFN alpha and TNF alpha, and the expression of ICAM-1 ly…

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment

2020

The serine/threonine kinase glycogen synthase kinase-3 (GSK-3) was initially identified because of its key role in the regulation of glycogen synthesis. However, it is now well-established that GSK-3 performs critical functions in many cellular processes, such as apoptosis, tumor growth, cell invasion, and metastasis. Aberrant GSK-3 activity has been associated with many human diseases, including cancer, highlighting its potential therapeutic relevance as a target for anticancer therapy. Recently, newly emerging data have demonstrated the pivotal role of GSK-3 in the anticancer immune response. In the last few years, many GSK-3 inhibitors have been developed, and some are currently being te…

Dynamical Hadrons: Case Studies of Meson-Meson and Meson-Baryon Molecules and Triangle Singularities

2020

In this thesis we use various methods to study the interaction of hadrons. We focus on topics related to exotic hadrons, such as tetraquarks from meson-meson interaction, pentaquarks from meson-baryon, and also triangular singularities. We show how experimental data can be explained with our theoretical models, and make predictions that can be compared with future experiments. In chapter 1 we show our method to describe meson-meson interactions, known as chiral unitary approach, showing how the interaction of pseudoscalars generates the f0(500), f0(980) and a0(980), which appear in the two articles discussed in this chapter: that of the eta_c -> eta pi+ pi- decay, and that of the a0(980)-f0…

Molekulārās sensibilizācijas profila pret suņiem saistība ar astmas un alerģiska rinīta kontroles rādītājiem

2022

Izpētes objekts Šis pētījums tika veikts, lai novērtētu suņa alergēnu molekulu sensitizāciju saistību ar astmu un alerģisko rinītu. Pētījuma metodoloģija Tika analizēti dati pacientiem, kuriem veikta ALEX vai ALEX2 paneļa testēšana un iegūts sensitizāciju profils katrai suņa alergēna molekulai (Can f 1, Can f 2, Can f 3, Can f 4, Can f 5 un Can f 6). Iegūtie dati tika analizēti kopā ar pacienta datiem par astmu un alerģisko rinītu. Rezultāti Molekulārā sensitizācija pret Can f 1, Can f 2 un Can f 6 uzrādīja statistiski nozīmīgu ietekmi uz astmas risku, taču, kad tika izslēgta sensitizācija pret citu dzīvnieku epitēliju, tikai Can f 1 un Can f 2 uzrādīja statistiski nozīmīgu ietekmi. Arī poz…

Myotonic dystrophy: candidate small molecule therapeutics

2017

Myotonic dystrophy type 1 (DM1) is a rare multisystemic neuromuscular disorder caused by expansion of CTG trinucleotide repeats in the noncoding region of the DMPK gene. Mutant DMPK transcripts are toxic and alter gene expression at several levels. Chiefly, the secondary structure formed by CUGs has a strong propensity to capture and retain proteins, like those of the muscleblind-like (MBNL) family. Sequestered MBNL proteins cannot then fulfill their normal functions. Many therapeutic approaches have been explored to reverse these pathological consequences. Here, we review the myriad of small molecules that have been proposed for DM1, including examples obtained from computational rational …

Treatment with a CO-releasing molecule (CORM-3) reduces joint inflammation and erosion in murine collagen-induced arthritis.

2008

Contains fulltext : 70589.pdf (Publisher’s version ) (Closed access) OBJECTIVE: CO-releasing molecules (CO-RMs) are a novel class of anti-inflammatory agents. We have examined the possible therapeutic effects of CORM-3 in collagen-induced arthritis (CIA). METHODS: Arthritis was induced in DBA-1/J mice by type II collagen. Animals were treated with CORM-3 (5 and 10 mg/kg/day, intraperitoneally) or the inactive compound iCORM-3 (10 mg/kg/day, intraperitoneally) unable to release CO, from days 22 to 31. Production of anti-type II collagen antibodies, cytokines and cartilage olimeric matrix protein (COMP) was evaluated by enzyme-linked immunosorbent assay, and prostaglandin E(2) (PGE(2)) by rad…